معرفی
Dr. Lei Peng serves as an Associate Research Scientist in the Department of Genetics at Yale School of Medicine and is affiliated with the Genomics, Genetics, and Epigenetics Program at Yale Cancer Center. Their research bridges fundamental genetic research with clinical applications in cancer immunotherapy and vaccine development.
Dr. Peng's research interests focus on genetics, genomics, epigenetics, cancer research, immunology, mRNA vaccines, CRISPR technology, and CAR-NK therapy. Their work represents an interdisciplinary approach that combines molecular biology with clinical translation, particularly in developing novel cancer treatments and vaccine platforms.
Recent publications demonstrate significant contributions to the field, with work appearing in high-impact journals including Nature Biotechnology (2024) and Nature Biomedical Engineering (2025). These publications reflect a research trajectory focused on improving therapeutic approaches through genetic engineering and immunological innovation.
Dr. Peng actively collaborates with several prominent researchers at Yale, including Sidi Chen (with two common publications), Carolina Lucas, Changin Oh, Daniel DiMaio, and Paul Renauer. These collaborations span multiple projects in immunology, cancer research, and genetic engineering, demonstrating an integrated research approach.
Current research efforts include developing modular vaccine platforms using lipid nanoparticle mRNA technology and conducting in vivo CRISPR screens to identify genetic checkpoints that could improve CAR-NK therapy for cancer treatment. These projects represent cutting-edge approaches to addressing challenges in cancer immunotherapy and vaccine development.
